However, we are not so far able to consider FLT3 pathway as a potential therapeutic target in cases with ETP in association with other tyrosine kinase or JAK-STAT inhibitors [14,24,30] or Bcl-2 inhibitors [31], as well as in AML [29,32]. This evidence concerns the gene BCL2 and acute myeloid leukemia.